Good
Mostly Aligned
Patient Risk:
Low
Summary
Within the provided evaluation scope (serious infections, mortality, malignancy, MACE, thrombosis), the claims described by the AI response are consistently marked supported and mapped to the corresponding label sections (Sections 5.1–5.5) with no contradictions identified.
Category Scores
Accurate Statements
Serious and sometimes fatal infections (including bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens) have been reported in patients receiving oral JAK inhibitors.
5.1 Serious Infections
Serious lower respiratory tract infections were reported with topical ruxolitinib in the clinical development program.
5.1 Serious Infections
OPZELURA should be avoided in patients with an active, serious infection (including localized infections), and OPZELURA should be interrupted if a patient develops a serious infection, opportunistic infection, or sepsis (do not resume until infection is controlled).
5.1 Serious Infections
A higher rate of all-cause mortality, including sudden cardiovascular death, was observed in a large randomized postmarketing safety study of an oral JAK inhibitor in RA patients.
5.2 Mortality
Malignancies, including lymphomas, were observed in clinical trials of oral JAK inhibitors used to treat inflammatory conditions.
5.3 Malignancy and Lymphoproliferative Disorders
A higher rate of malignancies (excluding non-melanoma skin cancer) and a higher rate of lymphomas were observed in a large randomized postmarketing safety study.
5.3 Malignancy and Lymphoproliferative Disorders
A higher rate of MACE (cardiovascular death, non-fatal MI, and non-fatal stroke) was observed in a large randomized postmarketing safety study.
5.4 Major Adverse Cardiovascular Events (MACE)
Discontinue OPZELURA in patients that have experienced a myocardial infarction or stroke.
5.4 Major Adverse Cardiovascular Events (MACE)
Thromboembolic events including DVT, PE, and arterial thrombosis have been reported; some resulted in death; and higher rates were observed versus TNF blockers in the large randomized postmarketing safety study.
5.5 Thrombosis
Avoid OPZELURA in patients at increased risk of thrombosis and discontinue OPZELURA if symptoms of thrombosis occur.
5.5 Thrombosis
Unsupported Statements
Contradictions
Important Omissions
No evaluation of other label elements is performed (e.g., boxed warning text verbatim, specific contraindications, detailed monitoring steps beyond the cited interruption/discontinue guidance for the listed risks, and contraindication language).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response’s evaluated claims within Sections 5.1–5.5 are aligned to label-supported risk statements and label-directed actions (avoid/interrupt/discontinue, monitoring). No contradictions or unsupported safety claims were identified in the provided risk-domain statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Scope-limited audit: the response does not verify or address other important label sections outside the provided risk domains (e.g., full boxed warning text, contraindications, complete dosing/administration, and additional monitoring/precautions).
Suggested Improvement
Provide or audit the full label text relevant to all requested categories (contraindications, boxed warning verbatim, dosing/administration, monitoring, and full adverse reaction summaries) rather than only the specified safety domains.